Athenex PP&E per Employee
Delisted
PP&E per Employee of Athenex (ATNX) as of Aug 23, 2026.
Get this data via API
Financial Data API
PP&E per Employee
0.00USD
Last updated:
PP&E per Employee of Athenex is 2026 0.00 USD. PP&E per Employee of Athenex was 2025 57,708.26 USD. It decreases by % lower compared to the previous year.
The Athenex PP&E per Employee history
3 Years
10 Years
25 Years
Max
PP&E per Employee
Date
PP&E per Employee
Jan 1, 2014
1,423.27 USD
Jan 1, 2015
10,605.40 USD
Jan 1, 2016
9,797.64 USD
Jan 1, 2017
16,274.87 USD
Jan 1, 2018
19,303.54 USD
Jan 1, 2019
53,914.00 USD
Jan 1, 2020
57,989.88 USD
Jan 1, 2021
57,708.26 USD
| YEAR | PP&E per Employee | YoY |
|---|---|---|
| 57,708.26USD | -0.49% | |
| 57,989.88USD | +7.56% | |
| 53,914.00USD | +179.30% | |
| 19,303.54USD | +18.61% | |
| 16,274.87USD | +66.11% | |
| 9,797.64USD | -7.62% | |
| 10,605.40USD | +645.14% | |
| 1,423.27USD | — |
Access this data via the Eulerpool API
Athenex Stock analysis
What does Athenex do? Athenex Inc was founded in 2003 and is headquartered in Buffalo, New York. The company specializes in the development and marketing of innovative drugs and therapies for the treatment of cancer and other serious diseases. Athenex's business model is based on collaboration with other companies and research institutions. The company works closely with academic partners to identify and develop new technologies and active ingredients. Athenex has also entered into several collaboration agreements with major pharmaceutical companies to facilitate the marketing of its products. The company has multiple divisions: Athenex Pharmaceutical Division, Athenex Oncology Division, and Athenex Pharmaceutical Technology Division. The Athenex Pharmaceutical Division focuses on the development and marketing of drugs for the treatment of cancer and other serious illnesses. The company has several promising drug candidates in its pipeline, including Oratopo, a drug for the treatment of breast cancer, and KX-2-391, a drug for the treatment of prostate cancer. The Athenex Oncology Division focuses on the development and marketing of innovative cancer treatment methods. The company has several promising therapy approaches in its pipeline, including an immunological cancer treatment based on activating the immune system to fight cancer cells. The Athenex Pharmaceutical Technology Division utilizes advanced technologies to improve the effectiveness and tolerability of drugs, including novel drug delivery systems and innovative packaging forms. Athenex also offers a wide range of products and services for the pharmaceutical industry, including drug development and manufacturing, as well as the supply of active ingredients and excipients. Overall, Athenex has a broad and interesting business model and a promising portfolio of drug candidates and therapy approaches in its pipeline. The company has also established strong partnerships with other companies and research institutions to advance its development and marketing of drugs and therapies.
Athenex is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Athenex stock
On Eulerpool you can find the complete historical development of PP&E per Employee Athenex since 2006 – with annual values, charts, and detailed analysis.
PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.
PP&E per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's Athenex historically and in real time.
Access this data via the Eulerpool API
Workforce — Athenex
All Key Metrics — Athenex
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth